A U G U S T 2 0 1 9 • O U T PA T I E N T S U R G E R Y. N E T • 5 5
All cataract surgeons would like
to use intracameral antibiotics
to fight post-operative infection
after cataract surgery. Two
recently approved products
could potentially eliminate the
compliance issues associated
with the complicated steroid
eye drop regimen following
cataract surgery.
• Dexycu (dexamethasone
intraocular suspension) 9%, the
first FDA-approved intraocular
steroid for the treatment of
post-op inflammation, is a great
example of how we can reduce
the drop burden for a patient.
This is a steroid that's injected
through a single shot into the
posterior chamber at the end of
cataract surgery. The sustained-release drug dis-
solves over the course of a month.
• Dextenza (dexamethasone ophthalmic insert
0.4 mg) is FDA-approved to treat both post-opera-
tive inflammation and pain. It is an intracanalicular
insert that is placed in the lower punctum following
cataract surgery. It is designed to deliver a steroid to
the ocular surface for 30 days following insertion.
EyePoint Pharmaceuticals
Dexycu
dexycu.com
Ocular Therapeutix
Dextenza
dextenza.com
• EYES WIDE OPEN Dr. Bailey views a video on administration of Dexycu (dexamethasone intraocular suspension) 9%, an
intraocular steroid for the treatment of post-op inflammation.
Joe
Paone
